June 18, 2020
Takeda Pharmaceutical is granting exclusive worldwide rights for clinical and preclinical psychiatry compounds to US biotech Neurocrine Biosciences in a strategic collaboration, the two companies said on June 16. Under the deal, the Japanese drug giant will receive an upfront...read more